What is Ashoka?
Ashoka, known scientifically as Saraca asoca, is a sacred and revered tree native to the Indian subcontinent, belonging to the Fabaceae (Legume) family. It is celebrated for its vibrant clusters of fragrant orange-red flowers and its dense, evergreen foliage. The tree is often associated with various cultural and religious traditions, particularly in Buddhism and Hinduism.
Beyond its ornamental and spiritual significance, the Ashoka tree's bark, flowers, and seeds have been traditionally utilized for their medicinal properties, most notably due to the presence of bioactive compounds like Saraca indica.
Other Names of Ashoka
- Saraca indica
- Ashok
- Sita Ashok
- Kankeli
- Hempushpa
Heading
<h3> Absolute Contraindications of Ashoka (Saraca asoca) </h3> <h4> Pregnancy (risk to developing pregnancy / early embryo) [In layman terms]</h4> <ul> <li> 🤰</li> <li> Recommendation: Avoid Ashoka (bark/extracts) during pregnancy; do not self-administer while trying to conceive without professional advice.</li> <li> Reasoning: Laboratory studies show Ashoka extracts strongly inhibit new blood-vessel formation (anti-angiogenic) in embryo vascular assays and contain compounds that alter uterine tissue dynamics; these effects could interfere with placental/embryonic blood supply or implantation.</li> <li> Scientific_Study_Title: In Vitro Anti Angiogenetic Activity of Traditional Plants Saraca asoca, Glycyrrhizia glabra and Curcuma longa Beneficial for Endometriosis Treatment</li> <li> Scientific_Study_Authors: Reshmi Nair, Shehna Sharaf, Lakshmi Sreedharan, Kizhiyedath Polachira Suja, K. K. Sabu</li> <li> Scientific_Study_Link: https://www.ijpsonline.com/articles/emin-vitroem-anti-angiogenetic-activity-of-traditional-plants-emsaraca-asocaem-emglycyrrhizia-glabraem-and-emcurcuma-longaem-benef-5404.html</li> <li> Scientific_Study_Excerpt: <p>The authors tested ethanolic extracts of Saraca asoca bark in the chick chorioallantoic membrane (CAM) assay to evaluate inhibition of new blood vessel formation. The S. asoca extract produced a marked anti-angiogenic effect (reported ~73.6% inhibition in their CAM model), higher than the reference agent used in that experiment. The study links this anti-angiogenic activity to high phenolic and flavonoid content and discusses the relevance for treating angiogenesis-dependent gynecological conditions (for example, endometriosis). Because angiogenesis is essential for implantation and placental development, the paper supports exercising caution with agents that strongly inhibit vessel growth during pregnancy. </p> <p>Based on these in vitro/embryo-model findings the authors propose that the anti-angiogenic properties, while potentially therapeutic for some gynecological disorders, could pose risk when angiogenesis is required (as in early pregnancy), and therefore advise caution until reproductive safety is proven in clinical studies.</p> </li> </ul> <h4> Known Sitosterolemia / genetic disorder of plant sterol handling [In layman terms]</h4> <ul> <li> ⚠️</li> <li> Recommendation: If you have sitosterolemia (a rare genetic condition that causes plant sterols to build up), do not take Ashoka preparations without specialist advice.</li> <li> Reasoning: Analytical studies show Ashoka parts and common Ashokarista preparations contain measurable β-sitosterol; people with sitosterolemia absorb and retain plant sterols, which can worsen cholesterol-related complications.</li> <li> Scientific_Study_Title: β-sitosterol in different parts of Saraca asoca and herbal drug ashokarista: Quali-quantitative analysis by liquid chromatography-mass spectrometry</li> <li> Scientific_Study_Authors: Anjum Gahlaut, Amey Shirolkar, Vikas Hooda, Rajesh Dabur</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/24083202/</li> <li> Scientific_Study_Excerpt: <p>This analytical study quantified β-sitosterol in various parts of Saraca asoca and in marketed Ashokarista preparations using HPLC-QTOF mass spectrometry. The authors found appreciable β-sitosterol amounts in bark and leaf extracts (examples: bark water extract ~170 ng/mL; leaf water extract ~123.5 ng/mL in their samples) and documented variability across plant parts and products. The paper highlights that herbal preparations are a source of dietary plant sterols and recommends careful quantitation for quality control and safety considerations.</p> <p>Clinically, β-sitosterol is harmless for most people but in sitosterolemia (a rare inherited disorder) elevated plant sterols accelerate atherosclerosis; therefore the detection of β-sitosterol in Ashoka supports advising avoidance in known sitosterolemia unless managed by a specialist.</p> </li> </ul> <h4> Unverified / adulterated commercial Ashoka (risk from substandard or substituted material) [In layman terms]</h4> <ul> <li> 🛑</li> <li> Recommendation: Avoid unlabelled or market-sourced Ashoka bark sold without quality certification; use only standardized, authenticated products from reputable suppliers.</li> <li> Reasoning: DNA barcoding and chemical profiling studies show widespread market adulteration and substitution of Ashoka with unrelated species; adulterants can reduce benefit and introduce unexpected toxicities.</li> <li> Scientific_Study_Title: DNA barcoding and NMR spectroscopy-based assessment of species adulteration in the raw herbal trade of Saraca asoca (Roxb.) Willd, an important medicinal plant</li> <li> Scientific_Study_Authors: Santhosh Kumar Jayanthinagar Urumarudappa, Navdeep Gogna, Steven G Newmaster, Krishna Venkatarangaiah, Ragupathy Subramanyam, Seethapathy Gopalakrishnan Saroja, Ravikanth Gudasalamani, Kavita Dorai, Uma Shaanker Ramanan</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27627901/</li> <li> Scientific_Study_Excerpt: <p>The authors used DNA barcoding and NMR spectroscopy to test raw herbal samples sold as Saraca asoca across market outlets. Analysis of 25 market samples revealed that over 80% were spurious, representing other plant species from multiple families rather than authentic S. asoca. The study emphasizes risks of reduced therapeutic effect and potential health hazards from substitution. The paper recommends stronger quality control, validated authentication and regulatory oversight of raw herbal trade to protect consumers.</p> <p>Given this evidence, consumption of non-authenticated Ashoka preparations is contraindicated because adulteration may expose users to unknown plant chemicals and safety concerns not present in genuine material.</p> </li> </ul> <h3> Relative Contraindications of Ashoka (Saraca asoca) </h3> <h4> Bleeding disorders or concurrent anticoagulant/antiplatelet therapy [In layman terms]</h4> <ul> <li> 🩸</li> <li> Recommendation: If you are on blood thinners (warfarin, DOACs, aspirin, clopidogrel) or have a bleeding tendency, consult your physician before using Ashoka; monitor blood counts if advised.</li> <li> Reasoning: Preclinical toxicity studies reported a significant fall in platelet counts at high experimental doses of Saraca extracts, suggesting potential added bleeding risk or platelet modulation when combined with anticoagulant medicines.</li> <li> Scientific_Study_Title: Phytochemical Screening and Toxicity Study of Saraca asoca Bark Methanolic Extract</li> <li> Scientific_Study_Authors: Manas Kumar Mukhopadhyay, Debjani Nath</li> <li> Scientific_Study_Link: https://ijp.arjournals.org/index.php/ijp/article/view/131</li> <li> Scientific_Study_Excerpt: <p>In a sub-acute oral toxicity study in mice, methanolic bark extract of S. asoca was administered at different doses and animals were evaluated for biochemical and hematological parameters. While most parameters and organ weights were unchanged, the study reported a statistically significant decrease in platelet count at the highest tested dose (1.2 g/kg), suggesting possible disturbance in platelet production at supratherapeutic exposures. The authors concluded the extract is largely non-toxic at moderate doses but flagged platelet reduction at high doses as a hematological effect warranting caution especially when bleeding risk is present.</p> </li> </ul> <h4> Concurrent cyclophosphamide (and potentially other cardiotoxic chemotherapies) - effects on drug toxicity/response [In layman terms]</h4> <ul> <li> 💊</li> <li> Recommendation: If you are receiving cyclophosphamide or related chemotherapy, discuss any Ashoka use with your oncologist - herbal extracts can alter drug effects (beneficially or by changing toxicity profiles).</li> <li> Reasoning: Animal studies report that Saraca indica extracts modified the cardiac toxicity produced by cyclophosphamide; this demonstrates that Ashoka phytochemicals can interact with drug-induced organ effects and may change how a medicine works or its side effects.</li> <li> Scientific_Study_Title: Cardioprotective effect of Saraca indica against cyclophosphamide induced cardiotoxicity in rats: a biochemical, electrocardiographic and histopathological study</li> <li> Scientific_Study_Authors: (authors listed on PubMed entry)</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/23543849/</li> <li> Scientific_Study_Excerpt: <p>In a rat model where cardiotoxicity was induced by a single high dose of cyclophosphamide, oral administration of alcoholic bark extract of Saraca indica reduced biochemical markers of cardiac injury (CK, CK-MB, LDH), improved oxidative enzyme levels (GSH, SOD, catalase), and mitigated histopathological myocardial damage. The extract also attenuated electrocardiographic abnormalities produced by the drug. The paper interprets these findings as cardioprotective and antioxidant effects of the herb, but clinically the result shows that Ashoka components can influence drug toxicity pathways and suggests need for medical supervision when combined with chemotherapy.</p> </li> </ul> <h4> Concomitant use with agents affecting bone marrow or hematopoiesis [In layman terms]</h4> <ul> <li> 🧪</li> <li> Recommendation: If you are on treatments that suppress bone marrow (certain chemotherapies, strong immunosuppressants), consult your doctor before taking Ashoka; monitoring blood counts may be advised.</li> <li> Reasoning: Experimental studies show Ashoka catechin fractions can modify marrow responses-sometimes protective-so concurrent use might change drug efficacy or blood counts.</li> <li> Scientific_Study_Title: Chemopreventive Potential of Major Flavonoid Compound of Methanolic Bark Extract of Saraca asoca in Benzene-induced Toxicity of Acute Myeloid Leukemia Mice</li> <li> Scientific_Study_Authors: (authors listed in the PMC article)</li> <li> Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538157/</li> <li> Scientific_Study_Excerpt: <p>The study evaluated a purified catechin from S. asoca bark in a benzene-induced mouse model of bone marrow toxicity/secondary acute myeloid leukemia. Treatment with the catechin improved hematological parameters (RBC, WBC, hemoglobin) and restored bone marrow cellularity compared with benzene exposure alone. The authors report modulation of cell-cycle regulators and protective antioxidant effects in marrow cells. While these protective effects are promising, they also demonstrate that Ashoka constituents influence hematopoiesis, so co-administration with marrow-active drugs may alter clinical blood counts or therapeutic responses and should be managed by a clinician.</p> </li> </ul>
Heading
<h4> Lowered platelet count / possible thrombocytopenia [Layman phrasing]</h4> <ul> <li> 🩺</li> <li> Side effect summary: High experimental doses of Ashoka extracts have been linked to reduced platelet counts in animal studies, which could increase bleeding risk.</li> <li> Recommendation: If you notice unusual bruising, bleeding gums, nosebleeds, or prolonged bleeding, stop the herb and seek medical care; people on blood thinners should consult their doctor first.</li> <li> Reasoning: A controlled toxicity study reported statistically significant platelet decreases at the highest tested dose, suggesting a dose-dependent hematological effect that could be clinically relevant in vulnerable people or when combined with anticoagulant medications.</li> <li> Severity Level: Moderate</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Title: Phytochemical Screening and Toxicity Study of Saraca asoca Bark Methanolic Extract</li> <li> Scientific_Study_Authors: Manas Kumar Mukhopadhyay, Debjani Nath</li> <li> Scientific_Study_Link: https://ijp.arjournals.org/index.php/ijp/article/view/131</li> <li> Scientific_Study_Excerpt: <p>In mice given repeated oral doses of methanolic Saraca asoca bark extract, most biochemical and organ-weight parameters remained normal, but the highest dose group showed a statistically significant drop in platelet count compared with controls. The authors interpreted this as a possible disturbance in platelet production at supratherapeutic doses while concluding that the extract was otherwise largely non-toxic in the tested range. The finding supports caution about bleeding risk when very high amounts of extract are consumed or when combined with other agents that affect coagulation.</p> </li> </ul> <h4> Potential effects on pregnancy/wound healing due to anti-angiogenic activity [Layman phrasing]</h4> <ul> <li> ⚠️</li> <li> Side effect summary: Ashoka extracts showed strong inhibition of new blood-vessel growth in embryo membrane assays; this could be harmful when new vessels must form (early pregnancy or tissue repair).</li> <li> Recommendation: Avoid during pregnancy and consult a healthcare professional before use around major surgery or where wound healing is critical.</li> <li> Reasoning: Anti-angiogenic action reduces growth of new capillaries; while useful for some gynecological problems, the same mechanism could compromise placental development or slow wound healing.</li> <li> Severity Level: Severe</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Title: In Vitro Anti Angiogenetic Activity of Traditional Plants Saraca asoca, Glycyrrhizia glabra and Curcuma longa Beneficial for Endometriosis Treatment</li> <li> Scientific_Study_Authors: Reshmi Nair, Shehna Sharaf, Lakshmi Sreedharan, Kizhiyedath Polachira Suja, K. K. Sabu</li> <li> Scientific_Study_Link: https://www.ijpsonline.com/articles/emin-vitroem-anti-angiogenetic-activity-of-traditional-plants-emsaraca-asocaem-emglycyrrhizia-glabraem-and-emcurcuma-longaem-benef-5404.html</li> <li> Scientific_Study_Excerpt: <p>The CAM assay study found ethanolic extracts of Saraca asoca significantly reduced angiogenesis in an embryo membrane model (reported ~73.6% inhibition). Authors linked the activity to high phenolic/flavonoid content and discussed clinical relevance for angiogenesis-dependent gynecological conditions. Because embryo implantation and placental growth depend on new vessel formation, such strong anti-angiogenic activity suggests potential risk in pregnancy or in clinical situations where robust angiogenesis is required (eg. healing), and underlies recommendations to avoid Ashoka in early pregnancy and where rapid tissue vascularization is necessary.</p> </li> </ul>
Heading
<h4> Anticoagulants / antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)</h4> <ul> <li> Interaction_Details: Ashoka extracts have been shown in animal studies to reduce platelet counts at high doses; combining with blood-thinning medicines could theoretically increase bleeding risk or alter hemostasis.</li> <li> Severity: Moderate</li> <li> Recommendation: Consult your prescribing clinician before starting Ashoka if you take any anticoagulant or antiplatelet drug; regular monitoring of blood counts and coagulation parameters may be advised.</li> <li> Scientific_Study_Available: Yes (preclinical hematology study)</li> <li> Scientific_Study_Link: https://ijp.arjournals.org/index.php/ijp/article/view/131</li> <li> Scientific_Study_Title: Phytochemical Screening and Toxicity Study of Saraca asoca Bark Methanolic Extract</li> <li> Scientfic_Study_Authors: Manas Kumar Mukhopadhyay, Debjani Nath</li> <li> Scientific_Study_Excerpt: <p>In sub-acute oral toxicity tests in mice, high doses of methanolic S. asoca bark extract produced a significant decline in platelet counts compared with control animals. Most other hematological and biochemical parameters remained within normal ranges. The platelet finding indicates that at higher exposures the extract may affect thrombopoiesis or platelet survival. Translating to humans, this raises the possibility that combining Ashoka with anticoagulant or antiplatelet drugs may increase bleeding risk or change therapy responses, and clinicians should therefore be informed and monitoring considered.</p> </li> </ul> <h4> Cyclophosphamide (and potentially similar cardiotoxic chemotherapies)</h4> <ul> <li> Interaction_Details: Animal studies showed co-administration of Saraca indica extract modified cyclophosphamide-induced cardiotoxic changes (reduced biomarkers and histological damage), indicating herb-drug modulation of chemotherapy toxicity pathways.</li> <li> Severity: Mild</li> <li> Recommendation: Inform your oncologist before using Ashoka during chemotherapy; do not start herbal preparations without specialist clearance-effects may be beneficial or may change drug pharmacodynamics.</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/23543849/</li> <li> Scientific_Study_Title: Cardioprotective effect of Saraca indica against cyclophosphamide induced cardiotoxicity in rats: a biochemical, electrocardiographic and histopathological study</li> <li> Scientfic_Study_Authors: (authors listed in the PubMed record)</li> <li> Scientific_Study_Excerpt: <p>In a Wistar rat model, a single high dose of cyclophosphamide produced biochemical markers of cardiac injury, ECG changes and histopathological myocardial damage. Administration of Saraca indica alcoholic bark extract (200 and 400 mg/kg) alongside cyclophosphamide reduced lipid peroxidation, normalized antioxidant enzyme levels (GSH, SOD, CAT), lowered cardiac injury enzymes (CK, CK-MB, LDH), and improved ECG and histology. The results indicate the herb has cardioprotective antioxidant properties that modify the drug’s organ toxicity; clinically this means Ashoka can alter the toxicity profile of chemotherapeutic agents and should be discussed with the treating team.</p> </li> </ul> <h4> Agents affecting bone marrow / hematopoiesis (myelotoxic drugs)</h4> <ul> <li> Interaction_Details: Saraca asoca catechin fractions have demonstrated marrow-protective effects in animal toxicant models; co-use with marrow-active drugs could alter blood counts or blunt intended drug effects.</li> <li> Severity: Mild</li> <li> Recommendation: If you are receiving myelotoxic treatment, discuss any Ashoka use with your clinician; blood counts should be monitored if both are used.</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538157/</li> <li> Scientific_Study_Title: Chemopreventive Potential of Major Flavonoid Compound of Methanolic Bark Extract of Saraca asoca in Benzene-induced Toxicity of Acute Myeloid Leukemia Mice</li> <li> Scientfic_Study_Authors: (authors listed in the PMC article)</li> <li> Scientific_Study_Excerpt: <p>In benzene-exposed mice (a model for marrow toxicity and secondary leukemia), treatment with a catechin purified from S. asoca bark ameliorated reductions in RBC, WBC and hemoglobin and improved bone marrow cellularity. The catechin modulated cell-cycle regulators and reduced indicators of DNA damage. While protective in this preclinical model, these results show that Ashoka constituents can change hematopoietic responses; when paired with drugs designed to suppress marrow (eg. some chemotherapies), this modulation could affect both toxicity and efficacy, warranting medical oversight and blood monitoring.</p> </li> </ul>
